Clinical significance and correlations between anti-β2 glycoprotein I IgA assays in antiphospholipid syndrome and/or systemic lupus erythematosus

Clinica Chimica Acta

Volumn 460, Issue , 2016, Pages 107-113

  Tebo, Anne E ^a,b   Willis, Rohan ^c   Jaskowski, Troy D ^b   Guerra, Marta ^d   Pierangeli, Silvia S ^c   Salmon, Jane ^d   Petri, Michelle ^e   Branch, D Ware ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d HOSPITAL FOR SPECIAL SURGERY   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti 2 glycoprotein I antibodies; Antiphospholipid syndrome; Diagnosis; Performance characteristics

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; IMMUNOGLOBULIN A; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; DIAGNOSTIC KIT; PHOSPHOLIPID ANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD SAMPLING; CLINICAL FEATURE; CONTROLLED STUDY; ELISA KIT; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; VEIN THROMBOSIS; BLOOD; DIAGNOSTIC KIT; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; STANDARDS; VENOUS THROMBOSIS;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; FEMALE; HUMANS; IMMUNOGLOBULIN A; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; REAGENT KITS, DIAGNOSTIC; VENOUS THROMBOSIS;

EID: 84976629806     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2016.06.025     Document Type: Article

References (26)

1. [1] Miyakis, S., Lockshin, M.D., Atsumi, T., Branch, D.W., Brey, R.L., Cervera, R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4 (2006), 295–306.
2. [2] Murthy, V., Willis, R., Romay-Penabad, Z., Ruiz-Limón, P., Martínez-Martínez, L.A., Jatwani, S., et al. Value of isolated IgA anti-β2-glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome. Arthritis Rheum. 65 (2013), 3186–3193.
3. [3] Fanopoulos, D., Teodorescu, M.R., Varga, J., Teodorescu, M., High frequency of abnormal levels of IgA anti-beta2-glycoprotein I antibodies in patients with systemic lupus erythematosus: relationship with antiphospholipid syndrome. J. Rheumatol. 25 (1998), 675–680.
4. [4] Diri, E., Cucurull, E., Gharavi, A.E., Kapoor, D., Mendez, E.A., Scopelitis, E., Wilson, W.A., Antiphospholipid (Hughes') syndrome in African-Americans: IgA aCL and abeta2 glycoprotein-I is the most frequent isotype. Lupus 8 (1999), 263–268.
5. [5] Lee, R.M., Branch, D.W., Silver, R.M., Immunoglobulin A anti-beta2-glycoprotein antibodies in women who experience unexplained recurrent spontaneous abortion and unexplained fetal death. Am. J. Obstet. Gynecol. 185 (2001), 748–753.
6. [6] Danowski, A., Kickler, T.S., Petri, M., Anti-beta2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus. J. Rheumatol. 33 (2006), 1775–1779.
7. [7] Staub, H.L., Franck, M., Ranzolin, A., Norman, G.L., Iverson, G.M., von Mühlen, C.A., Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that preferentially target domain 4 of beta2-GPI. J. Autoimmun. 27 (2006), 266–271.
8. [8] Sweiss, N.J., Bo, R., Kapadi, R., Manst, D., Mahmood, F., Adhikari, T., et al. IgA anti-beta2-glycoprotein I autoantibodies are associated with an increased risk of thromboembolic events in patients with systemic lupus erythematosus. PLoS One, 5, 2010, e12280.
9. [9] Mehrani, T., Petri, M., Association of IgA anti-beta2 glycoprotein I with clinical and laboratory manifestations of systemic lupus erythematosus. J. Rheumatol. 38 (2011), 64–68.
10. [10] Ruiz-García, R., Serrano, M., Martínez-Flores, J.Á., Mora, S., Morillas, L., Martín-Mola, M.Á., et al. Isolated IgA anti- β2 glycoprotein I antibodies in patients with clinical criteria for antiphospholipid syndrome. J. Immunol .Res., 2014, 2014, 704395.
11. [11] Cousins, L., Pericleous, C., Khamashta, M., Bertolaccini, M.L., Ioannou, Y., Giles, I., Rahman, A., Antibodies to domain I of β-2-glycoprotein I and IgA antiphospholipid antibodies in patients with ‘seronegative’ antiphospholipid syndrome. Ann. Rheum. Dis. 74 (2015), 317–319.
12. [12] Bertolaccini, M.L., Atsumi, T., Escudero Contreras, A., Khamashta, M.A., Hughes, G.R., The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. J. Rheumatol. 28 (2001), 2637–2643.
13. [13] Carmo-Pereira, S., Bertolaccini, M.L., Escudero-Contreras, A., Khamashta, M.A., Hughes, G.R., Value of IgA anticardiolipin and anti-beta2-glycoprotein I antibody testing in patients with pregnancy morbidity. Ann. Rheum. Dis. 62 (2003), 540–543.
14. [14] Samarkos, M., Davies, K.A., Gordon, C., Loizou, S., Clinical significance of IgA anticardiolipin and anti-β2-GPI antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Clin. Rheumatol. 25 (2006), 199–204.
15. [15] Martínez-Flores, J.A., Serrano, M., Alfaro, J., Mora, S., Paz-Artal, E., Morales, J.M., Serrano, A., Heterogeneity between diagnostic tests for IgA anti-beta2 glycoprotein I: explaining the controversy in studies of association with vascular pathology. Anal. Chem. 85 (2013), 12093–12098.
16. [16] Lockshin, M.D., Kim, Laskin, C.A., Guerra, M., Branch, D.W., Merrill, J., et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis. Rheum. 64 (2012), 2311–2318.
17. [17] Petri, M., Nelson, L., Weimer, F., Anderson, D., Darlington, T., Corash, L., The automated modified Russell viper venom time test for the lupus anticoagulant. J. Rheumatol. 18 (1991), 1823–1825.
18. [18] Brandt, J.T., Triplett, D.A., Alving, B., Scharrer, I., Criteria for the diagnosis of lupus anticoagulants: an update. Thromb. Haemost. 74 (1995), 1185–1190.
19. [19] Pierangeli, S.S., de Groot, P.G., Dlott, J., Favaloro, E., Harris, E.N., Lakos, G., et al. ‘Criteria’ aPL tests: report of a task force and preconference workshop at the 13th international congress on antiphospholipid antibodies, Galveston, Texas, April 2010. Lupus 20 (2011), 182–190.
20. [20] Lakos, G., Favaloro, E.J., Harris, E.N., Meroni, P.L., Tincani, A., Wong, R.C., Pierangeli, S.S., International consensus guidelines on anticardiolipin and anti-β2-glycoprotein I testing: report from the 13th international congress on antiphospholipid antibodies. Arthritis Rheum. 64 (2012), 1–10.
21. [21] Pierangeli, S.S., Favaloro, E.J., Lakos, G., Meroni, P.L., Tincani, A., Wong, R.C., Harris, E.N., Standards and reference materials for the anticardiolipin and anti-β2glycoprotein I assays: a report of recommendations from the APL task force at the 13th international congress on antiphospholipid antibodies. Clin. Chim. Acta 413 (2012), 358–360.
22. [22] de Groot, P.G., Derksen, R.H., de Laat, B., Twenty-two years of failure to set up undisputed assays to detect patients with the antiphospholipid syndrome. Semin. Thromb. Hemost. 34 (2008), 347–355.
23. [23] Pelkmans, L., Kelchtermans, H., de Groot, P.G., Zuily, S., Regnaualt, V., Wahl, D., et al. Variability in exposure of epitope G40-R43 of domain i in commercial anti-beta2-glycoprotein I IgG ELISAs. PLoS One, 8, 2013, e71402.
24. [24] Anis, S., Ahmed, E., Muzaffar, R., Prevalence of anti- beta2GPI antibodies and their isotypes in patients with renal diseases and clinical suspicion of antiphospholipid syndrome. J. Nephrol. 2 (2013), 181–189.
25. [25] Bizzaro, N., Pasini, P., Finco, B., False-positive reactions for IgA anti-phospholipid and anti-beta(2)-glycoprotein I antibodies in patients with IgA monoclonal gammopathy. Clin. Chem. 45 (1999), 2007–2010.
26. [26] Pengo, V., Tripodi, A., Reber, G., Rand, J.H., Ortel, T.L., Galli, M., et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardisation Committee of the International Society on thrombosis and Haemostasis. J. Thromb. Haemost. 7 (2009), 1737–1740.